Association of smoking and concomitant metformin use with cardiovascular events and mortality in people newly diagnosed with type 2 diabetes

Journal of Diabetes

Volumn 8, Issue 3, 2016, Pages 354-362

  Paul, Sanjoy K ^a   Klein, Kerenaftali ^a   Majeed, Azeem ^b   Khunti, Kamlesh ^c  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Cardiovascular risk; Metformin; Mortality; Smoking; Type 2 diabetes

Indexed keywords

CARDIOVASCULAR AGENT; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SMOKING; UNITED KINGDOM; ADVERSE EFFECTS; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE;

AGED; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SMOKING; SURVIVAL RATE;

EID: 84964022166     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12302     Document Type: Article

References (40)

1. International Diabetes Federation (IDF). IDF Diabetes Atlas, 6th edn. International Diabetes Federation, Brussels, 2013.
2. Yang Q, Cogswell ME, Flanders W etal. Trends in cardiovascular health metrics and associations with all-cause and cvd mortality among us adults. JAMA. 2012; 307: 1273-1283.
3. Fagard RH. Smoking amplifies cardiovascular risk in patients with hypertension and diabetes. Diabetes Care. 2009; 32 (Suppl. 2): S429-431.
4. Ding E, Hu FB. Smoking and type 2 diabetes: Underrecognized risks and disease burden. JAMA. 2007; 298: 2675-2676.
5. Jee SH, Foong AW, Hur NW, Samet JM. Smoking and risk for diabetes incidence and mortality in Korean men and women. Diabetes Care. 2010; 3: 2567-2572.
6. Critchley J, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: A systematic review. JAMA. 2003; 290: 86-97.
7. Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J. Active smoking and the risk of type 2 diabetes: A systematic review and meta-analysis. JAMA. 2007; 298: 2654-2664.
8. U.S. Department of Health and Human Services. The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General. Centers for Disease Control and Prevention, Atlanta, GA, 2014.
9. Madsbad S, McNair P, Christensen MS. Influence of smoking on insulin requirement and metabolic status in diabetes mellitus. Diabetes Care. 1980; 3: 41-43.
10. Eliasson MC, Jansson JH, Lindahl B, Stegmayr B. High levels of tissue plasminogen activator (tPA) antigen precede the development of type 2 diabetes in a longitudinal population study. The Northern Sweden MONICA study. Cardiovasc Diabetol. 2003; 2: 19.
11. Chaturvedi N, Rai H, Ben Shlomo Y. Lay diagnosis and health-care-seeking behaviour for chest pain in south Asians and Europeans. Lancet. 1997; 350: 1578-1583.
12. Sherman JJ. The impact of smoking and quitting smoking on patients with diabetes. Diabetes Spectrum. 2005; 18: 202-208.
13. Kenfield SA, Stampfer MJ, Rosner BA, Colditz GA. Smoking and smoking cessation in relation to mortality in women. JAMA. 2008; 299: 2037-2047.
14. Fan AZ, Rock V, Zhang X, Li Y, Elam-Evans L, Balluz L. Trends in cigarette smoking rates and quit attempts among adults with and without diagnosed diabetes, United States, 2001-2010. Prev Chronic Dis. 2013; 10: e160.
15. Chaturvedi N, Stevens L, Fuller JH, The World Health Organization Multinational Study Group. Which features of smoking determine mortality risk in former cigarette smokers with diabetes? The World Health Organization Multinational Study Group. Diabetes Care. 1997; 20: 1266-1272.
16. Kothari V, Stevens RJ, Adler AI etal. UKPDS 60: Risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke. 2002; 33: 1776-1781.
17. Turner RC, Millns H, Neil HA etal. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998; 316: 823-828.
18. Iversen B, Jacobsen B, Løchen M-L. Active and passive smoking and the risk of myocardial infarction in 24, 968 men and women during 11 year of follow-up: The Tromsø Study. Eur J Epidemiol. 2013; 28: 659-667.
19. Teo KK, Ounpuu S, Hawken S etal. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: A case-control study. Lancet. 2006; 368: 647-658.
20. Qin R, Chen T, Lou Q, Yu D. Excess risk of mortality and cardiovascular events associated with smoking among patients with diabetes: Meta-analysis of observational prospective studies. Int J Cardiol. 2013; 167: 342-350.
21. Chahal H, Bluemke DA, Wu CO etal. Heart failure risk prediction in the Multi-Ethnic Study of Atherosclerosis. Heart. 2014; 101: 58-64.
22. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care. 2014; 37 (Suppl. 1): S14-80.
23. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352: 854-865.
24. Lexis CPH, van der Horst ICC. Metformin for cardiovascular disease: Promise still unproven. Lancet Diabetes Endocrinol. 2014; 2: 94-95.
25. Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: A meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2011; 13: 221-228.
26. Boussageon R, Supper I, Bejan-Angoulvant T etal. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: A meta-analysis of randomised controlled trials. PLoS Med. 2012; 9: e1001204.
27. Majeed A. Sources, uses, strengths and limitations of data collected in primary care in England. Health Stat Q. 2004; 21: 5-14.
28. Khan NF, Harrison S, Rose P. Validity of diagnostic coding within the General Practice Research Database: A systematic review. Br J Gen Pract. 2010; 60: e128-136.
29. Williams T, Van Staa T, Puri S, Eaton S. Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource. Ther Adv Drug Saf. 2012; 3: 89-99.
30. Tate AR, Beloff N, Al-Radwan B etal. Exploiting the potential of large databases of electronic health records for research using rapid search algorithms and an intuitive query interface. J Am Med Inform Assoc. 2014; 21: 292-298.
31. Khan TA, Vohra HA, Paul S, Rosin MD, Patel RL. Axillary and tympanic membrane temperature measurements are unreliable early after cardiopulmonary bypass. Eur J Anaesthesiol. 2006; 23: 551-554.
32. Sadek AR, van Vlymen J, Khunti K, de Lusignan S. Automated identification of miscoded and misclassified cases of diabetes from computer records. Diabet Med. 2012; 29: 410-414.
33. Stamler J, Vaccaro O, Neaton JD, Wentworth D, The Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993; 16: 434-444.
34. Hankey GJ, Anderson NE, Ting RD etal. Rates and predictors of risk of stroke and its subtypes in diabetes: A prospective observational study. J Neurol Neurosurg Psychiatry. 2013; 84: 281-287.
35. Luo M, Guan X, Luczak ED etal. Diabetes increases mortality after myocardial infarction by oxidizing CaMKII. J Clin Invest. 2013; 123: 1262-1274.
36. Nilsson PM, Cederholm J, Eeg-Olofsson K etal. Smoking as an independent risk factor for myocardial infarction or stroke in type 2 diabetes: A report from the Swedish National Diabetes Register. Eur J Cardiovasc Prev Rehabil. 2009; 16: 506-512.
37. Al Delaimy WK, Manson JE, Solomon CG etal. Smoking and risk of coronary heart disease among women with type 2 diabetes mellitus. Arch Intern Med. 2002; 162: 273-279.
38. Faure P, Rossini E, Wiernsperger N, Richard MJ, Favier A, Halimi S. An insulin sensitizer improves the free radical defense system potential and insulin sensitivity in high fructose-fed rats. Diabetes. 1999; 48: 353-357.
39. Anedda A, Rial E, Gonzalez-Barroso MM. Metformin induces oxidative stress in white adipocytes and raises uncoupling protein 2 levels. J Endocrinol. 2008; 199: 33-40.
40. Stone MA, Charpentier G, Doggen K etal. Quality of care of people with type 2 diabetes in eight European countries: Findings from the Guideline Adherence to Enhance Care (GUIDANCE) study. Diabetes Care. 2013; 36: 2628-2638.